Table 1. Patient demographics and... | American Society of Hematology

Table 1.

Patient demographics and baseline characteristics

	R/I patients* (n = 33)	ND patients (n = 25)
Median age (range), y	13 (2-17)	13 (10-16)
Patients aged 1 to <12 y, n (%)	12 (36)	6 (24)
Patients aged 12 to <18 y, n (%)	21 (64)	19 (76)
Female, n (%)	12 (36)	12 (48)
Median height SDS (range)	−0.56 (−4.3 to 1.2)	0.06 (−0.9 to 1.7)
Pubertal status
Prepubertal, n (%)	9 (27)	4 (16)
Pubertal, n (%)	23 (70)	21 (84)
Missing, n (%)	1 (3)	0
Prior antineoplastic TKI therapies, n (%)
Imatinib	31 (93.9)	NA
Dasatinib	2 (6.1)	NA
Intolerant of imatinib/dasatinib, n (%)†	6 (18)/0	NA
Resistant to imatinib/dasatinib, n (%)†	28 (85)/2 (6)	NA

	R/I patients* (n = 33)	ND patients (n = 25)
Median age (range), y	13 (2-17)	13 (10-16)
Patients aged 1 to <12 y, n (%)	12 (36)	6 (24)
Patients aged 12 to <18 y, n (%)	21 (64)	19 (76)
Female, n (%)	12 (36)	12 (48)
Median height SDS (range)	−0.56 (−4.3 to 1.2)	0.06 (−0.9 to 1.7)
Pubertal status
Prepubertal, n (%)	9 (27)	4 (16)
Pubertal, n (%)	23 (70)	21 (84)
Missing, n (%)	1 (3)	0
Prior antineoplastic TKI therapies, n (%)
Imatinib	31 (93.9)	NA
Dasatinib	2 (6.1)	NA
Intolerant of imatinib/dasatinib, n (%)†	6 (18)/0	NA
Resistant to imatinib/dasatinib, n (%)†	28 (85)/2 (6)	NA

NA, not applicable; SDS, standard deviation score; TKI, tyrosine kinase inhibitor.

Patients were R/I to 1 prior TKI, either imatinib or dasatinib.

Three patients were both intolerant of and resistant to imatinib and are counted once as resistant and once as intolerant.